Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial

BACKGROUND: Shortly after the Coronavirus disease 2019 (COVID-19) pandemic, a considerable number of recovered patients reported persisting symptoms, especially neuropsychological manifestations, which were later named post-COVID syndrome (PCS). Immune dysregulation was suggested as one of the main...

Descripción completa

Detalles Bibliográficos
Autores principales: Farahani, Ramin Hamidi, Ajam, Ali, Naeini, Alireza Ranjbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064948/
https://www.ncbi.nlm.nih.gov/pubmed/37003990
http://dx.doi.org/10.1186/s12879-023-08172-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064948/
https://www.ncbi.nlm.nih.gov/pubmed/37003990
http://dx.doi.org/10.1186/s12879-023-08172-5

Ejemplares similares